Literature DB >> 34083092

"Is medical cannabis safe for my patients?" A practical review of cannabis safety considerations.

Caroline A MacCallum1, Lindsay A Lo2, Michael Boivin3.   

Abstract

Medical cannabis use is increasing worldwide. Clinicians are commonly asked by patients to provide guidance on its safety and efficacy. Although there has been an increase in research on the role of medical cannabis for a number of different conditions, we found that there was a paucity of clear safety guidance on its use. We aim to address this issue by answering two pertinent clinician safety questions: 1 Can medical cannabis be safely used in this patient? 2. What strategies can be used to ensure that any harms from medical cannabis are mitigated? To address these questions, we reviewed available evidence and provided expert clinical opinion to summarize the fundamental components for evaluating medical cannabis safety and strategies to reduce risk from its use. Our review resulted in a safety-focused framework for medical cannabis initiation and utilization. We provide clear recommendations for patients being considered for cannabis (e.g. precautions, contraindications and drug interactions). Risk mitigation strategies such as appropriate chemovar (strain) selection, routes of administration, and dosing are reviewed. As with any other pharmacotherapy, we review the key components of monitoring and address potential issues that may arise while using medical cannabis. We propose a structured assessment and monitoring strategy that can be used by clinicians recommending cannabis (CRC) to guide patients through each step of their cannabis journey. This framework can be used to ensure that medical cannabis utilization is associated with the lowest possible risk to the patient.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adverse Drug Reaction, ADR; Adverse Events, AE; Cannabidiol, CBD; Cannabinoid based medicines, CBM; Cannabinoids; Comorbidities; Contraindications; Drug Interactions, DI; Marijuana; Medical cannabis; Pharmacovigilance; Polypharmacy; Precautions; Safety; Side Effects; Tetrahydrocannabinol, THC

Mesh:

Substances:

Year:  2021        PMID: 34083092     DOI: 10.1016/j.ejim.2021.05.002

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  5 in total

1.  Potential Mechanisms Underlying Marijuana-Associated Periodontal Tissue Destruction.

Authors:  D A Scott; H Dukka; D Saxena
Journal:  J Dent Res       Date:  2021-09-13       Impact factor: 6.116

Review 2.  Inflammaging and Cannabinoids.

Authors:  Babak Baban; Hesam Khodadadi; Évila Lopes Salles; Vincenzo Costigliola; John C Morgan; David C Hess; Kumar Vaibhav; Krishnan M Dhandapani; Jack C Yu
Journal:  Ageing Res Rev       Date:  2021-10-15       Impact factor: 10.895

Review 3.  A Clinical Framework for Assessing Cannabis-Related Impairment Risk.

Authors:  Caroline A MacCallum; Lindsay A Lo; Carly A Pistawka; April Christiansen; Michael Boivin; Melissa Snider-Adler
Journal:  Front Psychiatry       Date:  2022-06-24       Impact factor: 5.435

4.  Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study.

Authors:  Lihi Bar-Lev Schleider; Raphael Mechoulam; Inbal Sikorin; Timna Naftali; Victor Novack
Journal:  Front Med (Lausanne)       Date:  2022-02-09

Review 5.  Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response.

Authors:  Yaron Ilan
Journal:  Front Med (Lausanne)       Date:  2022-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.